78 search results for: mechanism of disease
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis
This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares highlights how patients with type 2 inflammatory diseases often experience multimorbidities, with overlapping symptoms that amplify their overall disease burden and impact quality of life.
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares reviews the cellular and molecular pathways underlying atopic dermatitis and considers which biomarkers may one day serve as robust measures of disease modification, despite no validated options currently being available.
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies
Impact of Advanced Systemic Therapies on Disease Control in AD
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
ERS 2024 | What Do We Know About IL-33 Genetics?
Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
